Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer

Cyclin-dependent kinase (CDK)-7 inhibitors are emerging as promising drugs for the treatment of different types of cancer that show chemotherapy resistance. Evaluation of the effects of CDK7 inhibitor, THZ1, alone and combined with tamoxifen is of paramount importance. Thus, in the current work, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Attia, Yasmin M., Shouman, Samia A., Salama, Salama A., Ivan, Cristina, Elsayed, Abdelrahman M., Amero, Paola, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215326/
https://www.ncbi.nlm.nih.gov/pubmed/32340192
http://dx.doi.org/10.3390/ijms21082974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7215326/
https://www.ncbi.nlm.nih.gov/pubmed/32340192
http://dx.doi.org/10.3390/ijms21082974

Ejemplares similares